Unité de Fabrication des Médicaments (UMED) Stock Overview
Unité de Fabrication des Médicaments S.A. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
UMED Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Unité de Fabrication des Médicaments S.A Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | د.ت9.34 |
| 52 Week High | د.ت10.30 |
| 52 Week Low | د.ت6.87 |
| Beta | 0.056 |
| 1 Month Change | -4.50% |
| 3 Month Change | 16.90% |
| 1 Year Change | 33.43% |
| 3 Year Change | 31.55% |
| 5 Year Change | 8.60% |
| Change since IPO | -10.28% |
Recent News & Updates
Recent updates
Shareholder Returns
| UMED | TN Pharmaceuticals | TN Market | |
|---|---|---|---|
| 7D | 2.6% | 0.06% | 1.3% |
| 1Y | 33.4% | -1.9% | 38.0% |
Return vs Industry: UMED exceeded the TN Pharmaceuticals industry which returned -2% over the past year.
Return vs Market: UMED underperformed the TN Market which returned 38.1% over the past year.
Price Volatility
| UMED volatility | |
|---|---|
| UMED Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in TN Market | 5.6% |
| 10% least volatile stocks in TN Market | 2.3% |
Stable Share Price: UMED has not had significant price volatility in the past 3 months compared to the TN market.
Volatility Over Time: UMED's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1989 | n/a | Ridha Charfeddine | www.unimed.com.tn |
Unité de Fabrication des Médicaments S.A. develops, manufactures, markets, and sells generic and fashioned medicines in Tunisia and internationally. The company offers ophthalmic, ENT, inhalation and infusion solutions, injectable fluids and penicillin, and cephalosporin powders for various therapeutic areas under the UNIMED brand name. It exports its products to Africa, Asia, and Europe.
Unité de Fabrication des Médicaments S.A Fundamentals Summary
| UMED fundamental statistics | |
|---|---|
| Market cap | د.ت298.88m |
| Earnings (TTM) | د.ت22.22m |
| Revenue (TTM) | د.ت153.79m |
Is UMED overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UMED income statement (TTM) | |
|---|---|
| Revenue | د.ت153.79m |
| Cost of Revenue | د.ت65.65m |
| Gross Profit | د.ت88.13m |
| Other Expenses | د.ت65.92m |
| Earnings | د.ت22.22m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.69 |
| Gross Margin | 57.31% |
| Net Profit Margin | 14.45% |
| Debt/Equity Ratio | 40.6% |
How did UMED perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/11 08:51 |
| End of Day Share Price | 2026/02/11 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Unité de Fabrication des Médicaments S.A is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kais Kriaa | AlphaMena |
| Rim Ben Salah Gharbi | AlphaMena |
| Ghada Jendoubi | AlphaMena |